摘要
目的:研究Stathmin和Ki-67在子宫内膜样腺癌和正常子宫内膜中的表达差异,探讨Stathmin和Ki-6 7在子宫内膜样腺癌发生发展过程中的意义。方法:采用免疫组织化学法检测9 9例子宫内膜样腺癌及67例正常子宫内膜中Stathmin和Ki-67的表达情况。结果:子宫内膜样腺癌中Stathmin和Ki-67表达率分别为75.8%,70.7%,显著高于正常子宫内膜中的9.0%,4.5%,差异有统计学意义(P<0.05);Stathmin和Ki-67表达与子宫内膜样腺癌组织学分级相关(P<0.05),与患者年龄、临床分期、浸润深度、淋巴结转移及脉管侵犯无关(P>0.05);Stathmin表达和Ki-67表达呈正相关(r=0.672,P<0.05)。结论:子宫内膜样腺癌中Stathmin和Ki-67高表达可能共同参与子宫内膜样腺癌发生和分化;Stathmin和Ki-67表达呈正相关,提示Stathmin高表达可能与子宫内膜样腺癌高增殖性相关。
Objective： To investigate the expression of Stathmin and Ki-67 in endometrioid adenocarcinoma and its significance. Methods： Immunohistochemical staining for Stathmin and Ki-67 was performed in 99 cases of endometrioid adenocarcinoma and 67 cases of normal endometrium. Results： The expression rates of Stathmin and Ki-67 in endometrioid adenocarcinoma were 75.8% and 70.7%, respectively. The high expression rates of Stathmin and Ki-67 in normal endometrioma were 9.0% and 4.5%, respectively. The difference between endometrioid adenocarcinoma and normal endometrioma was significant （P〈0.05）. The expression of Stathmin and Ki-67 in endometrioid adenocarcinoma was related with its histology grading （P〈0.05）, but was not related with patients＇ age, clinical stage, invasion depth, lymph node metastasis and vascular invasion （P〉0.05）. The expression of Stathmin and Ki-67 were significantly positively correlated （r=0.672, P〈0.05）. Conclusion： The occurrence and differentiation of endometrial adenocarcinoma may be ralated with the high expressions of Stathmin and Ki-67. The expression of Stathmin and Ki-67 were significantly positively correlated indicated that the high expression of Stathmin may be associated with higher proliferation of the endometrial adenocarcinoma.
作者
熊中堂
江庆萍
刘少颜
丘福满
XIONG Zhongtang JIANG Qingping LIU Shaoyan QIU Fuman(Department of Pathology, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150 Institute for Chemical Carcinogenesis, School of Public Health, Guangzhou Medical University, Guangzhou 511436, China)
出处
《临床与病理杂志》
2017年第7期1361-1366,共6页
Journal of Clinical and Pathological Research
基金
国家自然科学基金(81602289)
广州市科技计划项目(201707010123)~~
